Search for: "AstraZeneca Pharmaceuticals, LP" Results 61 - 80 of 97
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
24 Mar 2012, 1:20 pm by Stewart Walsh
AstraZeneca Pharmaceuticals LP to surprise, and unpleasantly upend the patentee. [read post]
8 Nov 2012, 1:43 pm by Eric Guttag
AstraZeneca Pharmaceuticals LP to surprise, and unpleasantly upend the patentee. [read post]
6 Nov 2016, 10:13 pm by FDABlog HPM
United States Food and Drug Administration, No. 08-01495 (JDB) (here) and AstraZeneca Pharmaceuticals LP v. [read post]
15 Dec 2011, 10:17 am by Bexis
AstraZeneca Pharmaceuticals LP, No. 3:11-cv-04001-JAP-TJB, slip op. [read post]
30 Jul 2010, 4:06 am by Andrew Frisch
In Smith, the Third Circuit held that a pharmaceutical sales representative was not entitled to overtime pay because she qualified for the administrative exemption under the FLSA. [read post]
10 Nov 2008, 2:07 pm
AstraZeneca Pharmaceuticals LP, the court held that the complexity of having to prove the extent to which there actually was prescribing physician reliance - or none at all - or something in between - required dismissal of a third-party payer suit under Holmes v. [read post]
8 Jul 2007, 8:07 am
The printed version of the Sunday, July 8, 2007, issue of Parade contained an ad spread paid for by AstraZeneca Pharmaceuticals LP and AstraZeneca LP, members of the AstraZeneca group of companies (collectively, the "Company") for one of its products--Seroquel. [read post]
10 Sep 2012, 7:28 pm by FDABlog HPM
In July, after a court battle with FDA that started around mid-March when AstraZeneca Pharmaceuticals LP (“AstraZeneca”) sought to enjoin FDA from granting final ANDA approvals for generic SEROQUEL following FDA’s denial (without comment) of two citizen petitions AstraZeneca submitted to FDA last year concerning labeling carve-out issues, the U.S. [read post]
16 May 2012, 12:22 pm by Bexis
AstraZeneca Pharmaceuticals, LP, 634 F.3d 1352, 1360-66 (11th Cir. 2011) (plaintiff had not pleaded recoverable economic injury); Polk v. [read post]
26 Jan 2011, 1:31 am by Ben Vernia
In April of last year, we obtained a $520 million settlement with AstraZeneca LP and AstraZeneca Pharmaceuticals LP to resolve allegations that marketing of the anti-psychotic drug Seroquel for uses not approved as safe and effective by the FDA caused false claims to be submitted to federal health care programs. [read post]
Astrazeneca Pharmaceutical LP held a leave of absence or a leave extension can constitute a reasonable accommodation under the ADA “in some circumstances”, although in that case ultimately concluded the plaintiff could not show her request for twelve additional months of leave was facially reasonable. [read post]
Astrazeneca Pharmaceutical LP held a leave of absence or a leave extension can constitute a reasonable accommodation under the ADA “in some circumstances”, although in that case ultimately concluded the plaintiff could not show her request for twelve additional months of leave was facially reasonable. [read post]
18 Oct 2011, 9:33 am by Michelle Yeary
AstraZeneca Pharmaceuticals, LP, 634 F.3d 1352 (11th Cir. 2011)?  [read post]
16 Apr 2012, 1:29 am by FDABlog HPM
District Court are Motions for Summary Judgment filed by FDA and AstraZeneca Pharmaceuticals LP (here and here) concerning FDA’s approval of ANDAs for generic versions of SEROQUEL (quetiapine fumarate) Tablets and the Agency’s decision, discussed in a March 27, 2012 Letter Decision, concerning the scope and applicability of 3-year marketing exclusivity in that case.  [read post]
13 Nov 2014, 5:00 am
  Such vaccine litigation (Bexis’ first exposure to a pharmaceutical mass tort) was ultimately adjudged so inimical to the public health that Congress prohibited it. [read post]